LumiraDx Limited (LMDX)
| Market Cap | 2.40B |
| Revenue (ttm) | 234.31M |
| Net Income (ttm) | -93.88M |
| Shares Out | 252.70M |
| EPS (ttm) | -2.22 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,904 |
| Open | 9.59 |
| Previous Close | 9.73 |
| Day's Range | 9.29 - 9.60 |
| 52-Week Range | 7.15 - 11.09 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 15.06 (+58.9%) |
| Earnings Date | n/a |
About LMDX
LumiraDx Limited operates as a point of care diagnostic company. It focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. The company was formerly known as Point of Care Testing Limited and changed its name to LumiraDx Ltd in January 2018. LumiraDx Limited was incorporated in 2002 and is based in London, the United Kingdom.
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for LumiraDx stock is "Strong Buy." The 12-month stock price forecast is 15.06, which is an increase of 58.86% from the latest price.
News
Wall Street Analysts Believe LumiraDx Limited (LMDX) Could Rally 54%: Here's is How to Trade
The mean of analysts' price targets for LumiraDx Limited (LMDX) points to a 53.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among a...
LumiraDx Lab Analysis Confirms its COVID-19 Antigen Test Detects the Omicron Variant
LONDON, Jan. 14, 2022 /PRNewswire/ -- LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced that results from ongoing testing and monitoring of COVID-19 variants ...
LumiraDx has Commenced Shipments in Europe for its COVID-19 & Flu A/B Microfluidic Antigen Test
LONDON, Jan. 11, 2022 /PRNewswire/ -- LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced preliminary results for the fourth quarter of 2021 as well as expected...
LumiraDx CRP Test Achieves CE Marking
LONDON, Jan. 11, 2022 /PRNewswire/ -- LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced its C-reactive protein (CRP) Test has achieved CE Marking. The LumiraD...
LumiraDx COVID-19 & Flu A/B Rapid Antigen Test Achieves CE Marking
LONDON, Dec. 23, 2021 /PRNewswire/ -- LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced its SARS-CoV-2 & Flu A/B Antigen Test has achieved CE Marking. The mic...
LumiraDx Fast Lab Solutions Partners with Audere for At-Home Self- Collection Solution for use with SARS-CoV-2 RNA ST...
LONDON, Dec. 15, 2021 /PRNewswire/ -- LumiraDx (Nasdaq: LMDX) today announced a partnership with digital health non-profit Audere, to offer a self-collected COVID-19 nasal specimen collection kit that h...
Audere Receives FDA Emergency Use Authorization for HealthPulse@home COVID-19 Specimen Collection Test Kit
SEATTLE--(BUSINESS WIRE)-- #covid19--Audere, a digital health nonprofit developing solutions to improve global health, announced that it has received an Emergency Use Authorization (EUA) for HealthPulse...
FDA Reissues LumiraDx Fast Lab Solutions' EUA for SARS CoV-2 RNA STAR Complete Molecular Reagents to Allow High Throu...
LONDON, Dec. 1, 2021 /PRNewswire/ -- LumiraDx (Nasdaq: LMDX) announced today that the intended use for its Food and Drug Administration (FDA) Emergency Use Authorization (EUA) SARS-CoV-2 RNA STAR Comple...
LumiraDx Reports Third Quarter 2021 Financial Results
LONDON, Nov. 10, 2021 /PRNewswire/ -- LumiraDx (Nasdaq:LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for the quarter ended September 30, 2021. Reven...
LumiraDx to Announce Third Quarter 2021 Financial Results and Host Quarterly Conference Call on November 10
LONDON, Nov. 2, 2021 /PRNewswire/ -- LumiraDx (Nasdaq:LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its third quarter 2021 financial results on Wednesday, ...
LumiraDx Announces the Intended Use for its FDA EUA Authorized High Sensitivity COVID-19 Antigen Test has been Expand...
LONDON, Nov. 1, 2021 /PRNewswire/ -- Today, LumiraDx (Nasdaq: LMDX) a next-generation point of care (POC) diagnostics company announced that the intended use for its Food and Drug Administration (FDA) E...
Why Are LumiraDx Shares Trading Higher Today?
LumiraDx (NASDAQ:LMDX) has received emergency use approval by India's Central Drugs Standard Control Organisation for its SARS-CoV-2 Antigen test. The test detects antigen nucleocapsid protein from a n...
Here is how LumiraDx is making COVID-19 testing easier
LumiraDx (NASDAQ: LMDX) has received emergency user approval for the SARS-CoV-2 Antigen test in India from the Central Drugs Standard Organisation. The diagnostic Antigen test is designed to detect anti...
LumiraDx receives approval for its COVID-19 Antigen Test for use in India
LONDON, Oct. 20, 2021 /PRNewswire/ -- Today, LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostics testing company announced it has received emergency use approval by India's Central Drug...
LumiraDx Announces FDA EUA Submission for its SARS-CoV-2 & Flu A/B Rapid Antigen Test
LONDON, Oct. 15, 2021 /PRNewswire/ -- LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostic company, today announced it has submitted the LumiraDx SARS-CoV-2 & Flu A/B Test to the Food and...
CA Healthcare Acquisition Corp. and LumiraDx Limited Announce Effectiveness of Registration Statement and September 2...
BOSTON--(BUSINESS WIRE)--CA Healthcare and LumiraDx Announce Effectiveness of Registration Statement and September 28, 2021 Special Meeting to Approve Business Combination
LumiraDx and CA Healthcare Acquisition Corp Revise Transaction Terms, Expanded Strategic Roadmap for Next-Generation ...
BOSTON & LONDON--(BUSINESS WIRE)--LumiraDx and CA Healthcare Acquisition Corp Revise Transaction Terms, Expanded Strategic Roadmap for Next-Generation Point-of-Care Diagnostics
INVESTIGATION ALERT: Halper Sadeh LLP Investigates MCAD, CAHC, ROT, MUDS, LATN; Shareholders are Encouraged to Contac...
NEW YORK, April 29, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Mountain Crest Acquisition Corp. II (NASDAQ: MCAD) c...
Covid Testing Company LumiraDx Goes Public in SPAC
Apr.07 -- LumiraDx Ltd., a diagnostic company that produces Covid-19 tests, is going public through a reverse merger with a blank-check company.
Diagnostics company LumiraDX to go public via merger with SPAC in deal valued at about $5 billion
LumiraDX Ltd., a point of care diagnostics testing company, is going public via a merger with special purpose acquisition corporation, or SPAC, CA Healthcare Acquisition Corp. , in a deal with a pro for...
LumiraDx, a Next-Generation Point of Care Diagnostics Testing Company to List on Nasdaq via Merger with CA Healthcare...
BOSTON & LONDON--(BUSINESS WIRE)--LumiraDx, a Next-Generation Point of Care Diagnostics Testing Company to List on Nasdaq via Merger with CA Healthcare Acquisition Corp